Abstract
Clinical trial results indicate that the choice of antihypertensive agent can be a determinant of stroke protection, independent of blood pressure (BP) reduction. Angiotensin-converting enzyme inhibitors (ACE-Is) are effective for BP control and stroke protection, but their use may be limited by patient tolerability. Angiotensin receptor blockers appear to provide similar BP control compared with ACh-Is and may also offer the clinician the added benefit of primary and secondary stroke prevention, with the potential for fewer tolerability issues.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 115-122 |
| Number of pages | 8 |
| Journal | Postgraduate Medicine |
| Volume | 121 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2009 |
Keywords
- Angiotensin 2 type 1 receptor blockers
- Angiotensin-converting enzyme inhibitors
- Hypertension
- Renin-angiotensin system
- Stroke
ASJC Scopus subject areas
- Medicine(all)